ReBlast Precision (Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a 4-year, longitudinal study of 100 active-duty Navy SEALs. The goal of the study is to determine whether repeated blast exposure affects SEAL brain health and to develop an initial diagnostic testing protocol that detects repeated blast brain injury.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:
• Active-duty Navy SEAL Service Member
• Early career SEAL (0-2 years) or mid-late career SEAL (10-15 years)
• Age 18-50 years
• Males, regardless of race or ethnicity
Locations
United States
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Contact Information
Primary
Brian L Edlow, M.D.
bedlow@mgh.harvard.edu
617-724-6352
Backup
Michael A Gordon, B.s.
magordon@mgh.harvard.edu
617-724-6352
Time Frame
Start Date: 2025-10-14
Estimated Completion Date: 2029-08-31
Participants
Target number of participants: 100
Treatments
Experimental: Active-duty United States Navy SEALs
All SEAL participants will undergo comprehensive, longitudinal assessments of their exposures, cognitive performance, psychological health, physical symptoms, neuroimaging biomarkers, and blood biomarkers.
Related Therapeutic Areas
Sponsors
Leads: Massachusetts General Hospital
Collaborators: University of South Florida, Navy SEAL Foundation, Uniformed Services University of the Health Sciences, National Institutes of Health (NIH)